Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM

Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

Published:2024-04 Issue:4 Volume:47 Page:401-432
ISSN:0210-5705
Container-title:Gastroenterología y Hepatología
language:en
Short-container-title:Gastroenterología y Hepatología

Author:

Riveiro-Barciela Mar,Carballal Sabela,Díaz-González Álvaro,Mañosa Míriam,Gallego-Plazas Javier,Cubiella Joaquín,Jiménez-Fonseca Paula,Varela María,Menchén Luis,Sangro Bruno,Fernández-Montes Ana,Mesonero Francisco,Rodríguez-Gandía Miguel Ángel,Rivera Fernando,Londoño María-Carlota

Publisher

Elsevier BV

Reference320 articles.

1. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance;Martins;Nat Rev Clin Oncol,2019

2. GRADE system: classification of quality of evidence and strength of recommendation;Aguayo-Albasini;Cir Esp,2014

3. Liver toxicity as a limiting factor to the increasing use of immune checkpoint inhibitors;De Martin;JHEP Rep: Innov Hepatol,2020

4. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial;Ascierto;Lancet Oncol,2020

5. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review;Dougan;Gastroenterology,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Hepatobiliary complications of immune checkpoint inhibitors in cancer;Exploration of Targeted Anti-tumor Therapy;2024-07-26